Tiralosi Antonio, Cambria Manuela, Campanella Mariachiara, Paratore Vincenzo, Russo Cristina, Malaguarnera Lucia, Valle Maria Stella, Cambria Maria Teresa
Volunteers Organization, Via re Martino 84a, 95126 Catania, Italy.
Section of Medical Biochemistry, Department of Biomedical and Biotechnological Sciences, University of Catania, 95123 Catania, Italy.
Int J Mol Sci. 2025 Aug 19;26(16):8025. doi: 10.3390/ijms26168025.
Chronic obstructive pulmonary disease (COPD) is one of the leading causes of morbidity and mortality worldwide. Although conventional therapies are effective in controlling symptoms, they remain limited in altering the course of the disease and significantly reducing the chronic inflammation and oxidative stress underlying it. In this context, nanoparticles and nanomaterials are emerging as innovative tools capable of overcoming traditional pharmacological barriers due to their ability to deliver therapeutic oligonucleotides, antioxidants, and drugs in a targeted manner, modulate immune responses, and improve the bioavailability of active compounds. In particular, metal-organic frameworks (MOFs) stand out as ideal candidates for inhalable drug delivery in COPD, owing to their permanent crystalline porous structure, high specific surface area, and versatile chemical functionalization. This review provides the most recent preclinical evidence on the use of different nanoparticles in COPD, with a focus on the therapeutic and diagnostic potential of MOFs. It discusses their biocompatibility, drug loading strategies, and controlled release mechanisms and explores future perspectives for clinical translation.
慢性阻塞性肺疾病（COPD）是全球发病和死亡的主要原因之一。尽管传统疗法在控制症状方面有效，但在改变疾病进程以及显著减轻其潜在的慢性炎症和氧化应激方面仍然有限。在此背景下，纳米颗粒和纳米材料正作为创新工具崭露头角，因其能够以靶向方式递送治疗性寡核苷酸、抗氧化剂和药物，调节免疫反应，并提高活性化合物的生物利用度，从而克服传统药理学障碍。特别是，金属有机框架（MOF）因其永久的晶体多孔结构、高比表面积和多功能化学功能化，成为COPD吸入给药的理想候选材料。本综述提供了关于不同纳米颗粒在COPD中应用的最新临床前证据，重点关注MOF的治疗和诊断潜力。讨论了它们的生物相容性、药物负载策略和控释机制，并探讨了临床转化的未来前景。
